The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gavisova A.A.

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov

Kodyleva T.A.

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov

Nazarenko T.A.

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Healthcare of Russia

The use of testosterone-containing gel with reduced ovarian reserve in women with infertility in ART programs (IVF/ICSI)

Authors:

Gavisova A.A., Kodyleva T.A., Nazarenko T.A.

More about the authors

Journal: Russian Journal of Human Reproduction. 2022;28(5): 39‑45

DOI: 10.17116/repro20222805139

Read: 7590 times

Download PDF (RU)
Contact the author
Table of contents

THE USE OF TESTOSTERONE-CONTAINING GEL WITH REDUCED OVARIAN RESERVE IN WOMEN WITH INFERTILITY IN ART PROGRAMS (IVF/ICSI)
THE USE OF TESTOSTERONE-CONTAINING GEL WITH REDUCED OVARIAN RESERVE IN WOMEN WITH INFERTILITY IN ART PROGRAMS (IVF/ICSI)

To cite this article:

Gavisova AA, Kodyleva TA, Nazarenko TA. The use of testosterone-containing gel with reduced ovarian reserve in women with infertility in ART programs (IVF/ICSI). Russian Journal of Human Reproduction. 2022;28(5):39‑45. (In Russ.)
https://doi.org/10.17116/repro20222805139

Подписка 2026 Проблемы репродукции (Russian Journal of Human Reproduction)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Visualization of the mito­tic spindle in oocy­tes of patients with ovarian endo­metriosis as a prognostic factor for the effe­ctiveness of fertilization and early embryonic deve­lopment in IVF/ICSI programs. Russian Journal of Human Reproduction. 2025;(3):55-62
Influence of carriage of papi­llomavirus infe­ction on the course of exte­rnal geni­tal endo­metriosis in patients with intraepithelial lesion of the cervix. Russian Journal of Human Reproduction. 2025;(3):77-83
Expe­rimental mode­ling and treatment of endo­metriosis using bovhyaluronidase azoximer in an animal model. Russian Journal of Human Reproduction. 2025;(4):26-40
The Pate­rnity Test. Russian Journal of Human Reproduction. 2025;(4):41-45
Extracellular vesi­cles and their role in endo­metrial rece­ptivity in patients with recu­rrent implantation failure. Russian Journal of Human Reproduction. 2025;(4):46-52
Primary ovarian insu­fficiency: oppo­rtunities and prospects for the realization of reproductive function. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):42-47
The role of pelvic inflammatory diseases in reproductive function diso­rders in women. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):48-54
Characteristics of factors contributing to diso­rders of reproductive function in patients with adenomyosis. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):68-74
Comparative analysis of the effe­ctiveness of therapy for endo­metrial hype­rplasia in women of reproductive age. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):75-83
Diagnostic accu­racy of the aging males’ symptoms questionnaire for screening androgen defi­ciency in patients with psoriatic arthritis. Russian Journal of Preventive Medi­cine. 2025;(5):27-33
Abstract:

THE AIM OF THE STUDY

Study of the effectiveness of androgen priming in infertile patients with reduced ovarian reserve (OR) in ART programs (IVF/ICSI)

MATERIAL AND METHODS

A prospective cohort study included patients with infertility and reduced OR treated in assisted reproductive technology (ART) programs using in vitro fertilization (IVF). Based on the ESHRE criteria (Bologna criteria, 2011), the study group included 200 patients with infertility and SOR, among whom a treatment group was identified that received androgenic priming (12.5 mg of transdermal 1% testosterone (AndroGel 50 mg, Besin Healthcare, Belgium) for 1 month before the IVF/ICSI program. All patients have had a hormonal study of their androgenic profile by the immunochemiluminescent analysis (ICLA) and analysis of the parameters of oogenesis and embryogenesis.

RESULTS

Against the background of androgen priming with an androgen-containing gel, a statistically significant increase in the androstenedione concentration from 1.9±0.1 to 5.6±0.6 nmol/L (p<0.001) was observed in women with infertility and SOR. A statistically significant improvement in the indicators of oo- and embryogenesis was also noted: increase in the number of oocytes from 3.0 to 4.1 (p<0.001), the number of mature oocytes from 1.74 to 3.1 (p<0.001), zygotes from 1, 1 to 2.2 (p<0.001), blastocyst number from 0.7 to 1.5 (p<0.001), blastulation rate from 20 to 36.6% (p<0.001). There was a tendency of increasing the pregnancy rate from 8.8% to 14.3% (p=0.22).

CONCLUSION

Priming with a testosterone-containing gel improves the main indicators of the embryological stage in the IVF/ICSI program by the increasing of the number of mature oocytes, fertilization rate, blastocyst number and blastulation rate in patients with infertility and reduced ovarian reserve.

Keywords:

infertility
reduced ovarian reserve
androgens
androgen deficiency
androgen priming
testosterone
testosterone-containing gel
IVF/ICSI
reproductive age

Authors:

Gavisova A.A.

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov

Kodyleva T.A.

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov

Nazarenko T.A.

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Healthcare of Russia

Received:

02.09.2022

Accepted:

16.09.2022

Close metadata

References:

  1. Jeve YB, Bhandari HM. Effective treatment protocol for poor ovarian response: A systematic review and meta-analysis. Journal of Human Reproductive Sciences. 2016;9(2):70-81.  https://doi.org/10.4103/0974-1208.183515
  2. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Human Reproduction. 2011;26(7):1616-1624. https://doi.org/10.1093/humrep/der092
  3. Ryan KJ, Petro Z, Kaiser J. Steroid formation by isolated and recombined ovarian granulosa and tehcal cells. The Journal of Clinical Endocrinology and Metabolism. 1968;28(3):355-358.  https://doi.org/10.1210/jcem-28-3-355
  4. Horie K, Takakura K, Fujiwara H, Suginami H, Liao S, Mori T. Immunohistochemical localization of androgen receptor in the human ovary throughout the menstrual cycle in relation to oestrogen and progesterone receptor expression. Human Reproduction. 1992; 7(2):184-190.  https://doi.org/10.1093/oxfordjournals.humrep.a137614
  5. Suzuki T, Sasano H, Kimura N, Tamura M, Fukaya T, Yajima A, Nagura H. Immunohistochemical distribution of progesterone, androgen and oestrogen receptors in the human ovary during the menstrual cycle: relationship to expression of steroidogenic enzymes. Human Reproduction. 1994;9(9):1589-1595. https://doi.org/10.1093/oxfordjournals.humrep.a138757
  6. Hillier SG, Tetsuka M, Fraser HM. Location and developmental regulation of androgen receptor in primate ovary. Human Reproduction. 1997;12(1):107-111.  https://doi.org/10.1093/humrep/12.1.107
  7. Weil SJ, Vendola K, Zhou J, Adesanya OO, Wang J, Okafor J, Bondy CA. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. The Journal of Clinical Endocrinology and Metabolism. 1998;83(7):2479-2485. https://doi.org/10.1210/jcem.83.7.4917
  8. Harlow CR, Shaw HJ, Hillier SG, Hodges JK. Factors influencing follicle-stimulating hormone-responsive steroidogenesis in marmoset granulosa cells: effects of androgens and the stage of follicular maturity. Endocrinology. 1988;122(6):2780-2787. https://doi.org/10.1210/endo-122-6-2780
  9. Shaw HJ, Hillier SG, Hodges JK. Developmental changes in luteinizing hormone/human chorionic gonadotropin steroidogenic responsiveness in marmoset granulosa cells: effects of follicle-stimulating hormone and androgens. Endocrinology. 1989;124(4): 1669-1677. https://doi.org/10.1210/endo-124-4-1669
  10. Hillier SG, Ross GT. Effects of exogenous testosterone on ovarian weight, follicular morphology and intraovarian progesterone concentration in estrogen-primed hypophysectomized immature female rats. Biology of Reproduction. 1979;20(2):261-268.  https://doi.org/10.1095/biolreprod20.2.261
  11. Billig H, Furuta I, Hsueh AJ. Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. Endocrinology. 1993;133(5): 2204-2212. https://doi.org/10.1210/endo.133.5.8404672
  12. Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. The Journal of Clinical Investigation. 1998;101(12):2622-2629. https://doi.org/10.1172/JCI2081
  13. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Human Reproduction. 2003;18(3):598-603.  https://doi.org/10.1093/humrep/deg115
  14. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. The Journal of Clinical Endocrinology and Metabolism. 2003;88(12):5957-5962. https://doi.org/10.1210/jc.2003-030727
  15. Gervásio CG, Bernuci MP, Silva-de-Sá MF, Rosa-E-Silva AC. The role of androgen hormones in early follicular development. Obstetrics and Gynecology. 2014;2014:818010. https://doi.org/10.1155/2014/818010
  16. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Human Reproduction. 2000; 15(10):2129-2132. https://doi.org/10.1093/humrep/15.10.2129
  17. Bosdou JK, Venetis CA, Dafopoulos K, Zepiridis L, Chatzimeletiou K, Anifandis G, Mitsoli A, Makedos A, Messinis IE, Tarlatzis BC, Kolibianakis EM. Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial. Human Reproduction. 2016;31(5):977-985.  https://doi.org/10.1093/humrep/dew028
  18. Fábregues F, Peñarrubia J, Creus M, Manau D, Casals G, Carmona F, Balasch J. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Human Reproduction. 2009;24(2):349-359.  https://doi.org/10.1093/humrep/den428
  19. Massin N, Cedrin-Durnerin I, Coussieu C, Galey-Fontaine J, Wolf JP, Hugues JN. Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique--a prospective, randomized, double-blind study. Human Reproduction. 2006;21(5):1204-1211. https://doi.org/10.1093/humrep/dei481
  20. Kim CH, Ahn JW, Moon JW, Kim SH, Chae HD, Kang BM. Ovarian Features after 2 Weeks, 3 Weeks and 4 Weeks Transdermal Testosterone Gel Treatment and Their Associated Effect on IVF Outcomes in Poor Responders. Development and Reproduction. 2014; 18(3):145-52.  https://doi.org/10.12717/DR.2014.18.3.145
  21. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. The Journal of Clinical Endocrinology and Metabolism. 2005;90(7):3847-3853. https://doi.org/10.1210/jc.2005-0212
  22. Barbieri RL, Sluss PM, Powers RD, McShane PM, Vitonis A, Ginsburg E, Cramer DC. Association of body mass index, age, and cigarette smoking with serum testosterone levels in cycling women undergoing in vitro fertilization. Fertility and Sterility. 2005;83(2): 302-308.  https://doi.org/10.1016/j.fertnstert.2004.07.956
  23. Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. The Cochrane Database of Systematic Reviews. 2015;(11):CD009749. https://doi.org/10.1002/14651858
  24. Neves AR, Montoya-Botero P, Polyzos NP. Androgens and diminished ovarian reserve: the long road from basic science to clinical implementation. A comprehensive and systematic review with meta-analysis. American Journal of Obstetrics and Gynecology. 2022; 227(3):401-413.e18.  https://doi.org/10.1016/j.ajog.2022.03.051
  25. Singh AB, Lee ML, Sinha-Hikim I, Kushnir M, Meikle W, Rockwood A, Afework S, Bhasin S. Pharmacokinetics of a testosterone gel in healthy postmenopausal women. The Journal of Clinical Endocrinology and Metabolism. 2006;91(1):136-144.  https://doi.org/10.1210/jc.2005-1640
  26. Kim CH, Howles CM, Lee HA. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertility and Sterility. 2011;95(2): 679-683.  https://doi.org/10.1016/j.fertnstert.2010.07.1077
  27. Balasch J, Fábregues F, Peñarrubia J, Carmona F, Casamitjana R, Creus M, Manau D, Casals G, Vanrell JA. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Human Reproduction. 2006;21(7):1884-1893. https://doi.org/10.1093/humrep/del052
  28. Noventa M, Vitagliano A, Andrisani A, Blaganje M, Viganò P, Papaelo E, Scioscia M, Cavallin F, Ambrosini G, Cozzolino M. Testosterone therapy for women with poor ovarian response undergoing IVF: a meta-analysis of randomized controlled trials. Journal of Assisted Reproduction and Genetics. 2019;36(4):673-683.  https://doi.org/10.1007/s10815-018-1383-2
  29. Neves AR, Montoya-Botero P, Polyzos NP. The Role of Androgen Supplementation in Women with Diminished Ovarian Reserve: Time to Randomize, Not Meta-Analyze. Frontiers in Endocrinology. 2021; 12:653857. https://doi.org/10.3389/fendo.2021.653857
  30. Burger HG. Androgen production in women. Fertility and Sterility. 2002;77(suppl 4):3-5.  https://doi.org/10.1016/s0015-0282(02)02985-0
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.